Merck, Moderna begin late-stage study of mRNA cancer vaccine

This post was originally published on this site

The companies will study the safety and efficacy of the vaccine-Keytruda combination in patients with a type of skin cancer, compared to Keytruda alone.

Global recruitment for the trial has begun, with the first patients being enrolled in Australia, the companies said in a joint release.

Shares of Moderna rose 1% in premarket trading.